Peter Louis Duffy

Learn More
BACKGROUND Prior small to modest-sized studies suggest a benefit of intravascular ultrasound (IVUS) guidance in noncomplex lesions. Whether IVUS guidance is associated with improved clinical outcomes after drug-eluting stent (DES) implantation in an unrestricted patient population is unknown. METHODS AND RESULTS Assessment of Dual Antiplatelet Therapy(More)
BACKGROUND The relation between platelet reactivity and stent thrombosis, major bleeding, and other adverse events after coronary artery implantation of drug-eluting stents has been incompletely characterised. We aimed to determine the relation between platelet reactivity during dual therapy with aspirin and clopidogrel and clinical outcomes after(More)
BACKGROUND The incidence, predictors, and prognostic impact of post-discharge bleeding (PDB) after percutaneous coronary intervention (PCI) with drug-eluting stent (DES) implantation are unclear. OBJECTIVES This study sought to characterize the determinants and consequences of PDB after PCI. METHODS The prospective ADAPT-DES (Assessment of Dual(More)
Duke University Medical Center, Durham, North Carolina Stanford University Medical Center, Palo Alto, California Penn State Hershey Medical Center, Hershey, Pennsylvania Brigham and Women’s Hospital, Boston, Massachusetts Mayo Clinic, Rochester, Minnesota University of Illinois at Chicago/Jesse Brown VA Medical Center, Chicago, Illinois First Coast Heart(More)
BACKGROUND Chronic kidney disease (CKD) is associated with increased rates of adverse events after percutaneous coronary intervention. We sought to determine the impact of CKD on platelet reactivity in clopidogrel-treated patients and whether high platelet reactivity (HPR) confers a similar or differential risk for adverse events among patients with CKD and(More)
Assessment of Dual Antiplatelet Therapy With Drug-Eluting Stents (ADAPT-DES) was a prospective, multicenter registry of 8,582 consecutive stable and unstable patients who underwent percutaneous coronary intervention using a drug-eluting stent. We sought to identify key morphologic features leading to ST-segment elevation myocardial infarction (STEMI) versus(More)
OBJECTIVES This study compares outcomes of drug-eluting stents (DES) versus bare-metal stents (BMS) in patients undergoing saphenous vein graft (SVG) intervention. BACKGROUND The safety and efficacy of DES in patients undergoing SVG intervention is controversial. METHODS The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is a(More)
Brahmajee K. Nallamothu, MD, MPH, FACC, FAHA Carl L. Tommaso, MD, FACC, FAHA, FSCAI H. Vernon Anderson, MD, FACC, FAHA, FSCAI David J. Malenka, MD, FACC, FAHA Jeffrey L. Anderson, MD, FACC, FAHA, MACP Calin V. Maniu, MD, FACC, FAHA, FSCAI Joseph C. Cleveland Kevin W . McCabe , MD R . Adams Dudley, MD, MBA James D. Mortimer, Peter Louis Duffy, MD, MMM, FACC,(More)
OBJECTIVES This study evaluates outcomes and complications in patients treated with drug-eluting stents (DES) for "off-label" indications. BACKGROUND Drug-eluting stents have been effective in randomized trials, but their safety and efficacy for off-label indications has not been well studied. METHODS The STENT (Strategic Transcatheter Evaluation of New(More)
OBJECTIVES The purpose of this study was to compare the 9-month clinical outcomes of patients treated with paclitaxel-eluting stents (PES) or sirolimus-eluting stents (SES) for coronary artery stenosis. BACKGROUND The STENT (Strategic Transcatheter Evaluation of New Therapies) registry is the first multicenter registry in the U.S. to collect long-term(More)